解锁MHC ii激活癌症免疫治疗的代码

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2025-06-21 DOI:10.1016/j.critrevonc.2025.104813

Jiaqi Liu , Xueru Song , Wenqi Guo , Wanyi Liu , Shaokang Xu , Yan Yang , Xiaoyuan Chu , Zengjie Lei

{"title":"解锁MHC ii激活癌症免疫治疗的代码","authors":"Jiaqi Liu , Xueru Song , Wenqi Guo , Wanyi Liu , Shaokang Xu , Yan Yang , Xiaoyuan Chu , Zengjie Lei","doi":"10.1016/j.critrevonc.2025.104813","DOIUrl":null,"url":null,"abstract":"<div><div>Major Histocompatibility Complex class II (MHC II) molecules present tumor antigens to CD4 + T cells, playing a pivotal role in initiating anti-cancer immunity. Recent discoveries of MHC II expression on atypical antigen-presenting cells (APCs) have spurred interest in targeting MHC II for immunotherapy. Emerging therapies seek to enhance MHC II expression in tumors, particularly immunologically “cold” tumors with limited T-cell infiltration, to amplify CD4 + T cell-mediated anti-tumor responses. Clinical advances include MHC II-guided personalized vaccines, immune checkpoint blockade (ICB), and combination strategies showing promising efficacy. This review delineates MHC II-mediated immunoregulatory networks across professional and atypical APCs, explores their potential as biomarkers and therapeutic targets, and discusses predictive models of MHC II-antigen interactions to advance precision oncology. By elucidating the complexity of MHC II-driven immune regulation, this work aims to optimize immunotherapy design, address tumor heterogeneity, and foster tailored therapeutic approaches for diverse cancer types.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104813"},"PeriodicalIF":5.5000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unlock the code of MHC II-enabled Cancer immunotherapy\",\"authors\":\"Jiaqi Liu , Xueru Song , Wenqi Guo , Wanyi Liu , Shaokang Xu , Yan Yang , Xiaoyuan Chu , Zengjie Lei\",\"doi\":\"10.1016/j.critrevonc.2025.104813\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Major Histocompatibility Complex class II (MHC II) molecules present tumor antigens to CD4 + T cells, playing a pivotal role in initiating anti-cancer immunity. Recent discoveries of MHC II expression on atypical antigen-presenting cells (APCs) have spurred interest in targeting MHC II for immunotherapy. Emerging therapies seek to enhance MHC II expression in tumors, particularly immunologically “cold” tumors with limited T-cell infiltration, to amplify CD4 + T cell-mediated anti-tumor responses. Clinical advances include MHC II-guided personalized vaccines, immune checkpoint blockade (ICB), and combination strategies showing promising efficacy. This review delineates MHC II-mediated immunoregulatory networks across professional and atypical APCs, explores their potential as biomarkers and therapeutic targets, and discusses predictive models of MHC II-antigen interactions to advance precision oncology. By elucidating the complexity of MHC II-driven immune regulation, this work aims to optimize immunotherapy design, address tumor heterogeneity, and foster tailored therapeutic approaches for diverse cancer types.</div></div>\",\"PeriodicalId\":11358,\"journal\":{\"name\":\"Critical reviews in oncology/hematology\",\"volume\":\"214 \",\"pages\":\"Article 104813\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2025-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical reviews in oncology/hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S104084282500201X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S104084282500201X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

主要组织相容性复合体II类（MHC II）分子将肿瘤抗原呈递到CD4 + T细胞，在启动抗癌免疫中起关键作用。最近发现的MHC II在非典型抗原呈递细胞（APCs）上的表达激发了针对MHC II进行免疫治疗的兴趣。新兴疗法寻求增强肿瘤中MHC II的表达，特别是T细胞浸润有限的免疫“冷”肿瘤，以增强CD4 + T细胞介导的抗肿瘤反应。临床进展包括MHC ii引导的个性化疫苗、免疫检查点阻断（ICB）和显示有希望疗效的联合策略。本文概述了专业和非典型APCs中MHC ii介导的免疫调节网络，探讨了它们作为生物标志物和治疗靶点的潜力，并讨论了MHC ii抗原相互作用的预测模型，以推进精准肿瘤学。通过阐明MHC ii驱动的免疫调节的复杂性，本工作旨在优化免疫治疗设计，解决肿瘤异质性，并针对不同类型的癌症培养量身定制的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Unlock the code of MHC II-enabled Cancer immunotherapy

Major Histocompatibility Complex class II (MHC II) molecules present tumor antigens to CD4 + T cells, playing a pivotal role in initiating anti-cancer immunity. Recent discoveries of MHC II expression on atypical antigen-presenting cells (APCs) have spurred interest in targeting MHC II for immunotherapy. Emerging therapies seek to enhance MHC II expression in tumors, particularly immunologically “cold” tumors with limited T-cell infiltration, to amplify CD4 + T cell-mediated anti-tumor responses. Clinical advances include MHC II-guided personalized vaccines, immune checkpoint blockade (ICB), and combination strategies showing promising efficacy. This review delineates MHC II-mediated immunoregulatory networks across professional and atypical APCs, explores their potential as biomarkers and therapeutic targets, and discusses predictive models of MHC II-antigen interactions to advance precision oncology. By elucidating the complexity of MHC II-driven immune regulation, this work aims to optimize immunotherapy design, address tumor heterogeneity, and foster tailored therapeutic approaches for diverse cancer types.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.